Long-Term Outcomes After RFA of Thyroid Nodules.
Dr.Guttler’s comments on the letter to the editor.
1. Regrowth after Thyroid RF occurs.
2. Initial volume, vascularity, solidity, and location near dangerous structures are reasons for regrowth.
3. Patient must be aware of possible near for more RF sessions.
4. Prevention of treating a cancer with RF can be minimized by two biopsies and refusing to treat indeterminate nodules.
5. In 16 regrowing nodules post RF a case study failed to detect RF induced cancers by cutting needle BX of the edge.
6. RFA for small (<2 cm) follicular neoplasms. Their results showed that RFA represents an effective local tumor control method without distant metastasis for small (<2 cm) follicular neoplasms.
7. Call me at 310-393-8860 or email to [email protected] for details of thyroid RF treatment.
Long-Term Outcomes Following Thermal Ablation of Benign Thyroid Nodules as an Alternative to Surgery: The Importance of Controlling Regrowth (Endocrinol Metab 2019;34:117-23, Jung Suk Sim et al.
A substantial proportion of thermally ablated nodules can regrow, especially when their initial volume is large and they are followed for a longer period of time. We can and should inform patients that the treatment may not end with a single session of ablation and that multiple sessions may be necessary, so that patients can make an appropriate choice between ablation and surgery.
Regarding this issue, several factors should be considered to predict how many sessions will be needed. The initial nodule volume, the vascularity and solidity of the nodule, and its proximity to dangerous structures are related to the number of sessions of ablation . Dr. Kim also suggested that some ablated nodules with rapid regrowth might be malignant. These concerns involve two separate concepts: false-negative biopsy results before radiofrequency ablation (RFA) and RFA-induced malignant change of benign nodules. First, false-negative biopsy results before RFA can be minimized by conducting two biopsies before RFA, as recommended by the Korean RFA guideline [2,3]. Regarding the second concept underlying this concern, Ha et al.  evaluated pathologic findings of core-needle biopsy (CNB) specimens for 16 re-growing nodules after RFA. No atypical cells or neoplastic transformations were detected in the undertreated peripheral portion of treated regrowing benign nodules on the CNB specimens. In contrast, Dobrinja et al.  performed RFA for six nodules with indeterminate biopsy results (Bethesda categories 3 and 4). Two of the six nodules showed regrowth and surgery was performed. Their final pathologic results were min-imally invasive follicular carcinoma and follicular neoplasm of indeterminate malignant behavior. Therefore, they did not recommend RFA as a first-line therapy for thyroid nodules with in-determinate results. Most recently, Kim et al.  reported that according to published research, the tumor volume doubling time could not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasms.Dr. Kim’s last concern was the application of RFA for follicular variant papillary thyroid carcinoma and/or follicularcarcinoma. Could RFA yield a similar effect to that of partial diagnostic thyroid surgery, with respect to the prevention of future metastasis.
One pilot study about this concern has been published. Ha et al.  reported 5-year follow-up results of RFA for small (<2 cm) follicular neoplasms. Their results showed that RFA represents an effective local tumor control method without distant metastasis for small (<2 cm) follicular neoplasms.